← Back to Blog & Archive

16 November 2026 · APPG & Policy · Mixed Heritage & Equity

Four lighthouses, one cliff: Who counts the ships that go down?

By Yaser

Four lighthouses, one cliff: Who counts the ships that go down?

Professor John Forsythe told us that Tuesday the 17th of November would be the “Big Bang”, the day the findings of the independent review would be revealed. The agenda we since received tells a different story: a stakeholder meeting, workshops and “next steps”. A reveal is looking more like a consultation. We are still looking forward to hearing from him and will work with every stakeholder to shape the best possible outcome, but patients have waited long enough for answers, they must come first.

The Big Bang: A reveal is looking more like a consultation.

Before the Review: why the stem cell registry system is broken

We are delighted that this review was commissioned and has been taking place, because the system is broken. Patients diagnosed with life-threatening blood cancers and disorders arrive in desperate need of a stem cell match. The UK registries  each have  their own recruitment, set their own strategies and keep their own books. There is no cohesive or coherent national recruitment strategy and sadly many patients fall foul of this.

It is akin to four lighthouses standing on one cliff. Each was built to save ships and each keeps a careful log of the ships it saves. However, none of them logs the ships that go down where the beams of light do not overlap. Those unlogged ships are the patients who will never find a match at all. That is the unmet need. We do not know how many there are because no one is systematically counting them.

Until that number is known, no national recruitment strategy can be optimised.

A parliamentary group found that despite all their efforts, the UK registries  have consistently failed to improve self-sufficiency in providing UK stem cells for UK patients. Over the last decade the UK registry has more than doubled in size, yet the share of UK patients’ transplants coming from UK donors has fallen from 41% to 23%.

Inequity is not a footnote. White Northern European patients have a 72% chance of finding a well-matched unrelated donor, whereas patients from a minority ethnic background have a 37% chance only. The chances for mixed heritage patients are even worse still. They make up less than 2% of the register while the tissue types that would save them are the rarest on it.

Anthony Nolan’s own research shows Asian patients are 1.5 times more likely, and Black patients 1.3 times more likely, to die from complications within 5 years of a transplant than White patients.

And if that isn’t bad enough, we discovered that the inequity is baked in, albeit inadvertently. The Department of Health and Social Care set the financial-sustainability rule, NHS Blood and Transplant repeated it in their submission to an inquiry in 2023 and the registries abide by it. That is the equation that fails Black, Asian, minority ethnic and mixed heritage patients.

It stands to reason that a bus company that’s paid per fare will run its routes where the crowds are. Unless changes are made to the fare table, it can only be expected that buses will stop serving the villages.

These are among the issues that we expect the independent review to fix. Ultimately, we want a life-saving match for every patient that needs one.

Team Margot
Together, saving lives